ATP6V1C2 and renal cell carcinoma: Li and colleagues (Li et al., 2020) have reported that ATP6V1C2 is significantly down-regulated in RCC tissues and high expression of ATP6V1C2 predicts shorter overall survival in RCC patients from TCGA.